2019-01-15 : Press Release: Biomunex Pharmaceuticals signs a licensing agreement with Sanofi for the development of bi- and multi-specific antibodies
15/01/2019 : Communiqué de presse:Biomunex Pharmaceuticals signe un accord de licence avec Sanofi pour e développement d’anticorps bi- et multi-spécifiques
Interviews: Biomunex CSO defines lead compounds, early R&D plans
Interviews: Biomunex CEO on earlier deals for cancer drugs
Interviews: Bispecific Antibodies Close in on Cancer (GEN EXLUSIVES)
Press Release: nomination of Dr. Amigorena and Dr. Grabulovski as Key Advisers
Press Release: Biomunex presents novel data on BiXAb® antibodies
Press Release: nomination of the CSO Dr. Zhukovsky
